CDD on Novel Handheld Diagnostic Device Manufacturer

Secondary Research

• Analyzed competitive landscape, including technical strengths, and shortcomings of existing diagnostic offerings
• Identified M&A, investment, and cash flow comparable benchmarks for valuation triangulation (DCF, company comparison, and funding)

Primary Research

• Conducted 35 in-depth stakeholder interviews with clinical and technology experts to assess pain points, key users, and adoption nuances of the product across >10 primary clinical settings where this technology is applied
• Identified relevant stakeholder advocates to engage for adoption
• Tested pricing sensitivities and willingness to pay for key product features to model product adoption across multiple price points 

Quantitative Analysis

• Calculated current / projected target company valuation, including a sensitivity analysis key assumptions
• Projected revenues by key customer segment to 2027 and model parallel expenses including R&D costs, manufacturing COGS, and workforce expansion

‍

Key takeaways from DeciBio’s presentation to the client team included:

• Developed consensus with target company management projections to demonstrate profitability and rapid growth within 5 years post launch
• Global investment firm decided to invest >$200M in follow-on funding; target company is thriving and clinically present